GPT and metabolic dysfunction-associated steatohepatitis: In a subsequent clinical trial using open-label, quasiexperimental design involving 28 overweight or obese patients with non-alcoholic steatohepatitis (NASH) treated with metformin 2000 mg daily for 12 months, the researchers reported improvement in insulin resistance, alanine transaminase (ALT), and histology [140].